WallStSmart

Novartis AG ADR (NVS)vsSensus Healthcare Inc (SRTS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 205773% more annual revenue ($56.58B vs $27.48M). NVS leads profitability with a 23.9% profit margin vs -28.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

SRTS

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 4.7Quality: 8.5
Piotroski: 3/9Altman Z: 6.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-64.6%)

Margin of Safety

-64.6%

Fair Value

$91.23

Current Price

$151.40

$60.17 premium

UndervaluedFair: $91.23Overvalued
SRTSOvervalued (-6.3%)

Margin of Safety

-6.3%

Fair Value

$4.48

Current Price

$3.09

$1.39 premium

UndervaluedFair: $4.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$285.98B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

SRTS4 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

EPS GrowthGrowth
433.3%10/10

Earnings expanding 433.3% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.8010/10

Safe zone — low bankruptcy risk

Areas to Watch

NVS4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
2.552/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

SRTS4 concerns · Avg: 2.5/10
Market CapQuality
$46.92M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-17.1%2/10

ROE of -17.1% — below average capital efficiency

Revenue GrowthGrowth
-62.2%2/10

Revenue declined 62.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : SRTS

The strongest argument for SRTS centers on Price/Book, EPS Growth, Debt/Equity.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Bear Case : SRTS

The primary concerns for SRTS are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

NVS profiles as a declining stock while SRTS is a turnaround play — different risk/reward profiles.

SRTS carries more volatility with a beta of 1.19 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 35/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Sensus Healthcare Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.

Want to dig deeper into these stocks?